<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN" "http://jats.nlm.nih.gov/publishing/1.1d1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JMH</journal-id>
<journal-title-group>
<journal-title>Journal of Metabolic Health</journal-title>
</journal-title-group>
<issn pub-type="ppub">3105-4323</issn>
<issn pub-type="epub">2960-0391</issn>
<publisher>
<publisher-name>AOSIS</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">JMH-9-148</article-id>
<article-id pub-id-type="doi">10.4102/jmh.v9i1.148</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Series</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Targeting insulin and leptin in obesity management: A case series in metabolic health practice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-3761-1791</contrib-id>
<name>
<surname>Pua</surname>
<given-names>Jeffrey R.</given-names>
</name>
<xref ref-type="aff" rid="AF0001">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6333-8514</contrib-id>
<name>
<surname>Tidman</surname>
<given-names>Melanie M.</given-names>
</name>
<xref ref-type="aff" rid="AF0002">2</xref>
<xref ref-type="aff" rid="AF0003">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8910-9894</contrib-id>
<name>
<surname>White</surname>
<given-names>Dawn R.</given-names>
</name>
<xref ref-type="aff" rid="AF0004">4</xref>
<xref ref-type="aff" rid="AF0005">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8550-3317</contrib-id>
<name>
<surname>White</surname>
<given-names>Tim A.</given-names>
</name>
<xref ref-type="aff" rid="AF0006">6</xref>
<xref ref-type="aff" rid="AF0007">7</xref>
<xref ref-type="aff" rid="AF0008">8</xref>
</contrib>
<aff id="AF0001"><label>1</label>Department of Obesity Medicine, Duly Healthcare, Westmont, Illinois, United States of America</aff>
<aff id="AF0002"><label>2</label>School of Health Sciences, Liberty University, Lynchburg, Virginia, United States of America</aff>
<aff id="AF0003"><label>3</label>College of Graduate Health Studies, A.T. Still University, Mesa, Arizona, United States of America</aff>
<aff id="AF0004"><label>4</label>School of Health Professions, National University, San Diego, California, United States of America</aff>
<aff id="AF0005"><label>5</label>Glaser Center for Grounded Theory, Institute for Research and Theory Methodology, Poway, California, United States of America</aff>
<aff id="AF0006"><label>6</label>School of Health Sciences, American Public University, Charles Town, West Virginia, United States of America</aff>
<aff id="AF0007"><label>7</label>School of Business, University of Maryland Global Campus, Adelphi, Maryland, United States of America</aff>
<aff id="AF0008"><label>8</label>Glaser Center for Grounded Theory, Institute for Research and Theory Methodology, Poway, California, United States of America</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><bold>Corresponding author:</bold> Melanie Tidman, <email xlink:href="mtidman@liberty.edu">mtidman@liberty.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub"><day>19</day><month>10</month><year>2026</year></pub-date>
<pub-date pub-type="collection"><year>2026</year></pub-date>
<volume>9</volume>
<issue>1</issue>
<elocation-id>148</elocation-id>
<history>
<date date-type="received"><day>26</day><month>02</month><year>2026</year></date>
<date date-type="accepted"><day>26</day><month>08</month><year>2026</year></date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2026. The Authors</copyright-statement>
<copyright-year>2026</copyright-year>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>Licensee: AOSIS. This work is licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.</license-p>
</license>
</permissions>
<abstract>
<p>A low-carbohydrate ketogenic (LCK) diet implemented in a metabolic health practice was evaluated for its association with changes in fasting hyperinsulinemia, fasting hyperleptinemia and other metabolic biomarkers in adults with obesity. Six adults with obesity were recruited from the Duly Weight Loss Clinic in Westmont, Illinois, between 2022 and 2025. The cohort comprised three men and three women with a body mass index (BMI) &#x003E; 30 kg/m<sup>2</sup> who followed an LCK diet without anti-obesity pharmacotherapy. Participants were monitored for 12 months with visits every 30&#x2013;60 days that included counselling, coaching and fasting beta-hydroxybutyrate checks. Outcomes measured were changes in body weight, fasting insulin, fasting leptin and haemoglobin A1c (HbA1c). All six participants achieved clinically meaningful weight loss over 12 months. Mean weight reduction was 25&#x0025; from baseline. Fasting insulin decreased by a mean of 15.3 mIU/L, representing a 64&#x0025; reduction. Fasting leptin decreased by a mean of 25.5 ng/mL, corresponding to an 80&#x0025; reduction. Haemoglobin A1c decreased by a mean of 0.27&#x0025;. Weight reduction was accompanied by reductions in fasting insulin and fasting leptin, while HbA1c remained relatively stable. An LCK dietary approach combined with structured lifestyle support was associated with substantial weight loss and reductions in fasting insulin and circulating leptin, with HbA1c remaining relatively stable over 12 months. These findings support further investigation of an LCK diet within structured outpatient obesity management. An LCK diet within a structured obesity medicine programme was associated with clinically meaningful weight loss and reductions in fasting insulin and leptin concentrations.</p>
</abstract>
<kwd-group>
<kwd>obesity</kwd>
<kwd>insulin resistance</kwd>
<kwd>leptin resistance</kwd>
<kwd>metabolic syndrome</kwd>
<kwd>weight loss</kwd>
<kwd>hyperleptinemia</kwd>
<kwd>weight loss</kwd>
<kwd>low carbohydrate</kwd>
</kwd-group>
<funding-group>
<funding-statement><bold>Funding information</bold> This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.</funding-statement>
</funding-group>
</article-meta>
</front>
<body>
<sec id="s0001">
<title>Introduction</title>
<p>Guidelines for the practice of obesity medicine have evolved in clinical settings over the past few decades, driven by the American Board of Obesity Medicine and the Obesity Medicine Association.<sup><xref ref-type="bibr" rid="CIT0001">1</xref>,<xref ref-type="bibr" rid="CIT0002">2</xref></sup> These organisations have standardised education for obesity medicine providers and emphasise understanding the pathophysiology of obesity to drive improved weight-loss practices.<sup><xref ref-type="bibr" rid="CIT0002">2</xref></sup> Patient motivation and understanding of their care goals are essential parts of successful, long-term, sustainable weight changes. Weight regain is a common occurrence in obesity management.<sup><xref ref-type="bibr" rid="CIT0003">3</xref></sup> Throughout the weight-loss journey, it is associated with hyperinsulinemia (HI) and hyperleptinemia (HL). Individuals with obesity display high serum levels of leptin, and HL may contribute to diet-induced obesity. Reduction of serum leptin levels may influence weight regulation and insulin sensitivity.<sup><xref ref-type="bibr" rid="CIT0003">3</xref></sup> In 1988, Reaven described the role of insulin resistance and HI in the development of metabolic syndrome.<sup><xref ref-type="bibr" rid="CIT0004">4</xref></sup> The carbohydrate-insulin model of obesity links elevated blood glucose to HI and metabolic dysfunction, leading to subsequent fat accumulation.<sup><xref ref-type="bibr" rid="CIT0005">5</xref></sup> Food intake, total body fat and pancreatic peptide hormones such as insulin regulate leptin secretion, and HI may increase leptin levels.<sup><xref ref-type="bibr" rid="CIT0006">6</xref></sup> Other mechanisms have also been suggested to contribute to HL, including inflammation, alterations in leptin signalling and changes in leptin transport across the blood&#x2013;brain barrier.<sup><xref ref-type="bibr" rid="CIT0007">7</xref></sup> Zhao et al.<sup><xref ref-type="bibr" rid="CIT0003">3</xref></sup> demonstrated in transgenic mice that reductions in circulating leptin were associated with weight loss and reduced fat mass, further supporting investigation of leptin dynamics during weight reduction. The study concluded that the reduction in leptin was a major driver of glucagon-like peptide-1 (GLP-1) induced weight loss.<sup><xref ref-type="bibr" rid="CIT0003">3</xref></sup> The hypothalamus is a central component of hormone regulation, integrating signals from insulin, leptin, blood glucose and gastrointestinal hormones. Leptin reduction in mice protects against diet-induced weight gain. Zhao&#x2019;s et. al (2024) study in ALep mice shows that HL is a major driver of metabolic dysfunction and obesity, and when treated with a monoclonal leptin antibody, which reduced circulating leptin levels, there was significantly more weight loss and a greater decrease in fat mass, as well as subsequent reduced food intake.<sup><xref ref-type="bibr" rid="CIT0003">3</xref></sup> Previous studies have demonstrated that patients following a very-low-calorie diet (500 kcal/day &#x2013; 550 kcal/day) in a 10-week weight-loss programme experienced a 64&#x0025; reduction in plasma leptin levels, corresponding to a 14&#x0025; reduction in body weight.<sup><xref ref-type="bibr" rid="CIT0008">8</xref></sup> During weight-loss studies, a reduction in fasting insulin and leptin is commonly observed.<sup><xref ref-type="bibr" rid="CIT0003">3</xref>,<xref ref-type="bibr" rid="CIT0008">8</xref>,<xref ref-type="bibr" rid="CIT0009">9</xref>,<xref ref-type="bibr" rid="CIT0010">10</xref>,<xref ref-type="bibr" rid="CIT0011">11</xref></sup> Changes in plasma levels of fasting insulin, leptin and HbA1c have not been well studied in patients with obesity presenting to a weight-loss clinic who use therapeutic carbohydrate reduction (TCR) with a low-carbohydrate ketogenic (LCK) diet.<sup><xref ref-type="bibr" rid="CIT0010">10</xref></sup> Hyperinsulinemia and HL improve with anti-obesity GLP-1 treatment and bariatric surgery.<sup><xref ref-type="bibr" rid="CIT0003">3</xref>,<xref ref-type="bibr" rid="CIT0010">10</xref>,<xref ref-type="bibr" rid="CIT0012">12</xref>,<xref ref-type="bibr" rid="CIT0013">13</xref></sup> Many patients with obesity either lack access to GLP-1 treatment or do not wish to undergo bariatric surgery and therefore seek non-invasive weight-loss strategies that focus on lifestyle and dietary changes, such as the LCK diet.<sup><xref ref-type="bibr" rid="CIT0001">1</xref></sup> The LCK diet restricts carbohydrates to 5&#x0025; &#x2013; 10&#x0025; of total daily energy intake and usually to less than 20 g of carbohydrate daily.<sup><xref ref-type="bibr" rid="CIT0014">14</xref></sup> Subcutaneous fat cell size is correlated with insulin sensitivity, and a decrease in fat cell size and volume, which occurs with weight loss, improves insulin sensitivity.<sup><xref ref-type="bibr" rid="CIT0009">9</xref></sup> The arcuate nucleus (ARC), located within the hypothalamus, contains dense axonal networks with the highest concentration of leptin and insulin receptors among hypothalamic regions.<sup><xref ref-type="bibr" rid="CIT0009">9</xref></sup> It plays a central role in regulating hunger and eating behaviour by integrating signals from insulin, leptin and gastrointestinal hormones, including ghrelin, cholecystokinin and peptide tyrosine tyrosine (PYY).<sup><xref ref-type="bibr" rid="CIT0009">9</xref></sup> Participants in this case series received an LCK diet within a structured obesity medicine programme that included repeated behavioural coaching, biomarker monitoring and individualised follow-up over 12 months. The purpose of this case series was to describe changes in body weight, fasting insulin, fasting leptin and HbA1c during the 12-month intervention and to examine individual variability in these outcomes.</p>
</sec>
<sec id="s0002">
<title>Methods</title>
<sec id="s20003">
<title>Setting and recruitment</title>
<p>The case series was conducted at the Duly Obesity Medicine Clinic within the Duly Healthcare System, where clinical and laboratory data were accessible to the investigators. Patients were recruited between 2022 and 2025 via flyers distributed to colleagues at Duly Healthcare who expressed interest in participating and provided written informed consent. Participation was voluntary, and they received written instructions explaining that clinic participation included weight monitoring and fasting laboratory testing to measure baseline fasting serum insulin, fasting serum leptin and HbA1c. Six cases were selected from the clinical population to provide equal representation of men and women among patients who completed the 12-month LCK diet intervention and had baseline and follow-up insulin and leptin measurements available for analysis.</p>
</sec>
<sec id="s20004">
<title>Eligibility criteria</title>
<p>Six patients presented to the Obesity Medicine Clinic and consented after the study&#x2019;s purpose and procedure were explained. Participants were required to sign informed consent and agree to comply with the study protocol. Eligibility for participation in the case series was based on a baseline body mass index (BMI) greater than 30 kg/m<sup>2</sup> and the intention to treat obesity using lifestyle modification, including TCR with the LCK diet alone, rather than anti-obesity pharmacotherapy. There was no upper BMI limit, and comorbidities such as hypertension, prediabetes, cardiovascular disease, obstructive sleep apnoea (OSA), gout and prior bariatric surgery did not preclude participation.</p>
</sec>
<sec id="s20005">
<title>Intervention</title>
<p>Participants received written educational materials describing the nutrition plan, meal planning strategies, approved food lists, recipes and behavioural coaching promoting positive stages of change. Lifestyle recommendations also included increasing physical activity as tolerated, intermittent fasting when appropriate and improved sleep hygiene. Treatment decisions were made collaboratively between the clinician and participant and adjusted every 30&#x2013;60 days with monitoring to reinforce progress. Participants received individualised coaching to support adherence to the LCK diet. Follow-up visits every 30&#x2013;60 days focused on reinforcing dietary adherence, reviewing weight and laboratory results, addressing implementation barriers and encouraging sustainable lifestyle change. Dietary adherence was assessed by participant self-report and home beta-hydroxybutyrate (BHB) monitoring. Participants were encouraged to achieve the goal of BHB readings &#x003E; 0.5 mmol/L. Rather than a single educational encounter, the intervention emphasised repeated counselling and individualised support throughout the 12-month study, with available biomarker results used to reinforce progress and encourage long-term adherence.</p>
</sec>
<sec id="s20006">
<title>Behavioural intervention</title>
<p>Participants were taught using the Stages of Change model by Prochaska and DiClemente<sup><xref ref-type="bibr" rid="CIT0015">15</xref></sup> to identify and communicate positive behaviour changes for weight loss. This model of behavioural change was reinforced during follow-up visits.<sup><xref ref-type="bibr" rid="CIT0015">15</xref></sup></p>
</sec>
<sec id="s20007">
<title>Data collection and monitoring</title>
<p>Baseline height in centimetres (cm), weight in kilograms (kg), BMI in kg per metre squared (kg/m<sup>2</sup>) and blood pressure were recorded at the initial visit and subsequent visits every 30&#x2013;60 days. Participants were instructed to fast for 12 h before blood collection. Baseline laboratory testing was performed between 07:00 and 10:00 for all participants except Case 1, whose initial sample was obtained at 15:00. Laboratory measurements were obtained periodically during the 12-month follow-up; however, intermediate laboratory assessments were not performed at uniform time points across all participants. Baseline and 12-month measurements were used for the primary comparison because these timepoints were available across the cohort. Laboratory testing was performed through the Duly Health and Care Laboratory and Quest Diagnostics using standard protocols. Insulin and leptin were measured using automated immunoassays, and BHB was measured using an enzymatic assay on Roche Cobas instrumentation at Quest Diagnostics. Laboratory BHB measurements were obtained intermittently and were not available at uniform time points across participants. Intra-assay and inter-assay coefficients of variation for these assays were &#x003C; 5&#x0025; and &#x003C; 8&#x0025;, respectively. HbA1c was measured using high-performance liquid chromatography on the Bio-Rad D-100 Glycohemoglobin Analyser at Duly Health and Care Laboratory, with intra-assay and inter-assay coefficients of variation &#x003C; 2&#x0025;. Laboratory values were reported as provided by the laboratories; no conversion factors were applied.</p>
</sec>
</sec>
<sec id="s0008">
<title>Case descriptions</title>
<sec id="s20009">
<title>Case 1</title>
<p>A 72-year-old woman (162.6 cm, a weight of 118.8 kg and a BMI of 45.1 kg/m<sup>2</sup>) with hypertension, coronary artery disease, prediabetes and arthritis. She had a Roux-en-Y gastric bypass in 2003, but experienced persistent obesity, with body weight remaining between 112 kg and 118 kg from 2011 through 2024. Her medications included rosuvastatin and valsartan/hydrochlorothiazide (HCTZ). She elected treatment with the LCK diet without anti-obesity pharmacotherapy.</p>
</sec>
<sec id="s20010">
<title>Case 2</title>
<p>A 69-year-old (162.6 cm, a weight of 111 kg and a BMI of 42.2 kg/m<sup>2</sup>) with hypertensive heart disease, prediabetes, hypothyroidism, OSA and obesity. She has a history of 1A breast cancer treated with mastectomy and reconstruction in 2021&#x2013;2022 and was receiving exemestane. Her medications included spironolactone, levothyroxine, amlodipine, labetalol and Natural Porcine (NP) thyroid. She participated in the Silver Sneakers fitness programme and elected treatment with the LCK diet without anti-obesity pharmacotherapy.</p>
</sec>
<sec id="s20011">
<title>Case 3</title>
<p>A 61-year-old woman (162.6 cm, a weight of 93.9 kg and a BMI of 35.5 kg/m<sup>2</sup>) with anxiety, hypothyroidism, OSA, prediabetes, dyslipidaemia and obesity. Her medications include escitalopram, levothyroxine and rosuvastatin. She elected treatment with the LCK diet without anti-obesity pharmacotherapy.</p>
</sec>
<sec id="s20012">
<title>Case 4</title>
<p>A 66-year-old man (179.1 cm, a weight of 143.8 kg and a BMI of 44.5 kg/m<sup>2</sup>) with coronary artery disease, hypertension, congestive heart failure, metabolic syndrome, gout and OSA. His medications included clopidogrel, rosuvastatin, lisinopril, colchicine, allopurinol and aspirin. He reported previous success with the Atkins diet before presenting for treatment with the LCK diet without anti-obesity pharmacotherapy.</p>
</sec>
<sec id="s20013">
<title>Case 5</title>
<p>A 58-year-old man (190.5 cm, a weight of 124.5 kg and a BMI of 34.3 kg/m<sup>2</sup>) with prediabetes, hypertriglyceridaemia, hyperuricemia with gout, obesity and anxiety. His medications included allopurinol and buspirone. A former marathon runner, he elected treatment with the LCK diet without anti-obesity pharmacotherapy.</p>
</sec>
<sec id="s20014">
<title>Case 6</title>
<p>A 45-year-old man (177.8 cm, a weight of 128 kg and a BMI of 40.5 kg/m<sup>2</sup>) with hypertension, hyperuricemia, low high-density lipoprotein (HDL) cholesterol and obesity. His medications included amlodipine or valsartan, allopurinol and indomethacin as needed. He reported bicycling approximately 20 miles per week and elected to undergo LCK diet treatment without anti-obesity pharmacotherapy.</p>
</sec>
<sec id="s20015">
<title>Ethical considerations</title>
<p>Ethical clearance to conduct this study was obtained from the Liberty University Institutional Review Board (No. IRB-FY25-26-1150). Written informed consent for publication of de-identified clinical information was obtained from all participants.</p>
</sec>
</sec>
<sec id="s0016">
<title>Results</title>
<p>All six participants completed the 12-month follow-up period and were included in the final analysis. Baseline demographic and anthropometric characteristics are presented in <xref ref-type="table" rid="T0001">Table 1</xref> and establish the clinical context for interpreting subsequent metabolic and outcome measures.</p>
<table-wrap id="T0001">
<label>TABLE 1</label>
<caption><p>Baseline characteristics of the study participants.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Case</th>
<th valign="top" align="center">Age (years)</th>
<th valign="top" align="center">Sex</th>
<th valign="top" align="center">Height (cm)</th>
<th valign="top" align="center">Weight (kg)</th>
<th valign="top" align="center">BMI (kg/m<sup>2</sup>)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">1</td>
<td align="center">72</td>
<td align="center">F</td>
<td align="center">162.6</td>
<td align="center">118.8</td>
<td align="center">45.1</td>
</tr>
<tr>
<td align="left">2</td>
<td align="center">69</td>
<td align="center">F</td>
<td align="center">162.6</td>
<td align="center">111.1</td>
<td align="center">42.2</td>
</tr>
<tr>
<td align="left">3</td>
<td align="center">61</td>
<td align="center">F</td>
<td align="center">162.6</td>
<td align="center">93.9</td>
<td align="center">35.5</td>
</tr>
<tr>
<td align="left">4</td>
<td align="center">66</td>
<td align="center">M</td>
<td align="center">179.1</td>
<td align="center">143.8</td>
<td align="center">44.5</td>
</tr>
<tr>
<td align="left">5</td>
<td align="center">58</td>
<td align="center">M</td>
<td align="center">190.5</td>
<td align="center">124.3</td>
<td align="center">34.3</td>
</tr>
<tr>
<td align="left">6</td>
<td align="center">45</td>
<td align="center">M</td>
<td align="center">177.8</td>
<td align="center">127.9</td>
<td align="center">40.5</td>
</tr>
<tr>
<td align="left">Mean &#x00B1; s.d.</td>
<td align="center">61.8 &#x00B1; 9.7</td>
<td align="center">-</td>
<td align="center">172.5 &#x00B1; 11.7</td>
<td align="center">120.0 &#x00B1; 16.8</td>
<td align="center">40.4 &#x00B1; 4.5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>BMI, body mass index; s.d., standard deviation; F, female; M, male.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Clinically meaningful reductions in total body weight were observed across the case series. As shown in <xref ref-type="table" rid="T0002">Table 2</xref>, the mean baseline weight was 120 kg &#x00B1; 16.8 kg and decreased to 89.7 kg &#x00B1; 14.1 kg after 12 months, representing a mean absolute reduction of 30.2 kg &#x00B1; 8.3 kg and a 25.2&#x0025; &#x00B1; 5.5&#x0025; decrease from baseline. Individual participant weight changes are detailed in <xref ref-type="table" rid="T0002">Table 2</xref>. Blood pressure was monitored throughout follow-up, with no reported episodes of hypotension. No gout attacks occurred during the 12-month intervention. Antihypertensive and gout medication regimens remained unchanged in four participants. In Case 5, allopurinol was increased from 100 mg to 300 mg daily because of elevated uric acid without a reported gout attack, while in Case 6, the amlodipine component of amlodipine or valsartan was reduced from 10 mg to 5 mg daily during routine clinical monitoring.</p>
<table-wrap id="T0002">
<label>TABLE 2</label>
<caption><p>Changes in body weight following 12 months of a low-carbohydrate ketogenic diet.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Case</th>
<th valign="top" align="center">Baseline weight (kg)</th>
<th valign="top" align="center">12-month weight (kg)</th>
<th valign="top" align="center">Change (kg)</th>
<th valign="top" align="center">Change (&#x0025;)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">1</td>
<td align="center">118.8</td>
<td align="center">81.6</td>
<td align="center">&#x2212;37.2</td>
<td align="center">&#x2212;31.3</td>
</tr>
<tr>
<td align="left">2</td>
<td align="center">111.1</td>
<td align="center">81.2</td>
<td align="center">&#x2212;29.9</td>
<td align="center">&#x2212;26.9</td>
</tr>
<tr>
<td align="left">3</td>
<td align="center">93.9</td>
<td align="center">71.2</td>
<td align="center">&#x2212;22.7</td>
<td align="center">&#x2212;24.2</td>
</tr>
<tr>
<td align="left">4</td>
<td align="center">143.8</td>
<td align="center">102.1</td>
<td align="center">&#x2212;41.7</td>
<td align="center">&#x2212;29.0</td>
</tr>
<tr>
<td align="left">5</td>
<td align="center">124.3</td>
<td align="center">94.3</td>
<td align="center">&#x2212;30.0</td>
<td align="center">&#x2212;24.1</td>
</tr>
<tr>
<td align="left">6</td>
<td align="center">127.9</td>
<td align="center">108.0</td>
<td align="center">&#x2212;19.9</td>
<td align="center">&#x2212;15.6</td>
</tr>
<tr>
<td align="left">Mean &#x00B1; s.d.</td>
<td align="center">120.0 &#x00B1; 16.8</td>
<td align="center">89.7 &#x00B1; 14.1</td>
<td align="center">&#x2212;30.2 &#x00B1; 8.3</td>
<td align="center">&#x2212;25.2 &#x00B1; 5.5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>LCK, low-carbohydrate ketogenic; s.d., standard deviation.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Changes in fasting insulin levels are presented in <xref ref-type="table" rid="T0003">Table 3</xref>. Mean fasting insulin decreased from 20.9 mIU/L &#x00B1; 16.0 mIU/L at baseline to 5.5 mIU/L &#x00B1; 2.2 mIU/L at 12 months, representing a mean reduction of 15.3 mIU/L &#x00B1; 14.1 mIU/L and a 63.8&#x0025; &#x00B1; 20.6&#x0025; decrease from baseline. Individual responses varied, with Case 1 demonstrating a comparatively small reduction in fasting insulin from 6.2 mIU/L to 4.6 mIU/L despite substantial weight loss (<xref ref-type="table" rid="T0002">Table 2</xref> and <xref ref-type="table" rid="T0003">Table 3</xref>).</p>
<table-wrap id="T0003">
<label>TABLE 3</label>
<caption><p>Changes in fasting insulin and haemoglobin A1c following 12 months of a low-carbohydrate ketogenic diet.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Case</th>
<th valign="top" align="center">Baseline insulin (mIU/L)</th>
<th valign="top" align="center">12-month insulin (mIU/L)</th>
<th valign="top" align="center">Change (mIU/L)</th>
<th valign="top" align="center">Change (&#x0025;)</th>
<th valign="top" align="center">Baseline HbA1c (&#x0025;)</th>
<th valign="top" align="center">12-month HbA1c (&#x0025;)</th>
<th valign="top" align="center">Change (&#x0025;)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">1</td>
<td align="center">6.2</td>
<td align="center">4.6</td>
<td align="center">&#x2212;1.6</td>
<td align="center">&#x2212;25.8</td>
<td align="center">5.4</td>
<td align="center">4.9</td>
<td align="center">&#x2212;0.5</td>
</tr>
<tr>
<td align="left">2</td>
<td align="center">29.7</td>
<td align="center">4.8</td>
<td align="center">&#x2212;24.9</td>
<td align="center">&#x2212;83.8</td>
<td align="center">5.3</td>
<td align="center">5.0</td>
<td align="center">&#x2212;0.3</td>
</tr>
<tr>
<td align="left">3</td>
<td align="center">18.3</td>
<td align="center">5.9</td>
<td align="center">&#x2212;12.4</td>
<td align="center">&#x2212;67.8</td>
<td align="center">5.8</td>
<td align="center">5.3</td>
<td align="center">&#x2212;0.5</td>
</tr>
<tr>
<td align="left">4</td>
<td align="center">48.9</td>
<td align="center">9.7</td>
<td align="center">&#x2212;39.2</td>
<td align="center">&#x2212;80.2</td>
<td align="center">5.5</td>
<td align="center">5.6</td>
<td align="center">+0.1</td>
</tr>
<tr>
<td align="left">5</td>
<td align="center">11.6</td>
<td align="center">4.4</td>
<td align="center">&#x2212;7.2</td>
<td align="center">&#x2212;62.1</td>
<td align="center">5.7</td>
<td align="center">5.6</td>
<td align="center">&#x2212;0.1</td>
</tr>
<tr>
<td align="left">6</td>
<td align="center">10.4</td>
<td align="center">3.8</td>
<td align="center">&#x2212;6.6</td>
<td align="center">&#x2212;63.5</td>
<td align="center">5.4</td>
<td align="center">5.1</td>
<td align="center">&#x2212;0.3</td>
</tr>
<tr>
<td align="left">Mean &#x00B1; s.d.</td>
<td align="center">20.9 &#x00B1; 16.0</td>
<td align="center">5.5 &#x00B1; 2.2</td>
<td align="center">&#x2212;15.3 &#x00B1; 14.1</td>
<td align="center">&#x2212;63.8 &#x00B1; 20.6</td>
<td align="center">5.52 &#x00B1; 0.19</td>
<td align="center">5.25 &#x00B1; 0.30</td>
<td align="center">&#x2212;0.27 &#x00B1; 0.23</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>HbA1c, haemoglobin A1c; LCK, low-carbohydrate ketogenic; s.d., standard deviation.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Changes in fasting leptin levels are presented in <xref ref-type="table" rid="T0004">Table 4</xref>. Mean fasting leptin decreased from 32.3 ng/mL &#x00B1; 19.6 ng/mL at baseline to 6.8 ng/mL &#x00B1; 6.2 ng/mL at 12 months, corresponding to a mean reduction of 25.5 ng/mL &#x00B1; 14.2 ng/mL and an 80.3&#x0025; &#x00B1; 7.7&#x0025; decrease. Changes in HbA1c are presented in <xref ref-type="table" rid="T0003">Table 3</xref>. Mean HbA1c decreased from 5.52&#x0025; at baseline to 5.25&#x0025; at 12 months, representing a mean absolute reduction of 0.27&#x0025;.</p>
<table-wrap id="T0004">
<label>TABLE 4</label>
<caption><p>Changes in fasting leptin following 12 months of a low-carbohydrate ketogenic diet.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Case</th>
<th valign="top" align="center">Baseline leptin (ng/mL)</th>
<th valign="top" align="center">12-month leptin (ng/mL)</th>
<th valign="top" align="center">Change (ng/mL)</th>
<th valign="top" align="center">Change (&#x0025;)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">1</td>
<td align="center">18.8</td>
<td align="center">3.2</td>
<td align="center">&#x2212;15.6</td>
<td align="center">&#x2212;83.0</td>
</tr>
<tr>
<td align="left">2</td>
<td align="center">55.1</td>
<td align="center">16.3</td>
<td align="center">&#x2212;38.8</td>
<td align="center">&#x2212;70.4</td>
</tr>
<tr>
<td align="left">3</td>
<td align="center">55.3</td>
<td align="center">13.0</td>
<td align="center">&#x2212;42.3</td>
<td align="center">&#x2212;76.5</td>
</tr>
<tr>
<td align="left">4</td>
<td align="center">34.7</td>
<td align="center">2.9</td>
<td align="center">&#x2212;31.8</td>
<td align="center">&#x2212;91.6</td>
</tr>
<tr>
<td align="left">5</td>
<td align="center">8.9</td>
<td align="center">2.2</td>
<td align="center">&#x2212;6.7</td>
<td align="center">&#x2212;75.3</td>
</tr>
<tr>
<td align="left">6</td>
<td align="center">20.8</td>
<td align="center">3.1</td>
<td align="center">&#x2212;17.7</td>
<td align="center">&#x2212;85.1</td>
</tr>
<tr>
<td align="left">Mean &#x00B1; s.d.</td>
<td align="center">32.3 &#x00B1; 19.6</td>
<td align="center">6.8 &#x00B1; 6.2</td>
<td align="center">&#x2212;25.5 &#x00B1; 14.2</td>
<td align="center">&#x2212;80.3 &#x00B1; 7.7</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>LCK, low-carbohydrate ketogenic; s.d., standard deviation.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The study participants were encouraged to achieve a BHB goal of &#x003E; 0.5 mmol/L, which is the widely accepted value for nutritional ketosis. However, available laboratory BHB measurements provided evidence of intermittent nutritional ketosis, with BHB readings as low as &#x003E; 0.1 mmol/L even in the presence of ongoing weight loss in the study sample.</p>
</sec>
<sec id="s0017">
<title>Discussion</title>
<p>Over 12 months, substantial reductions in body weight were accompanied by a marked decline in fasting serum insulin and leptin levels in this cohort of adults with obesity treated with an LCK nutrition plan. The parallel changes in anthropometric and hormonal markers suggest coordinated metabolic adaptation during sustained weight reduction in a real-world clinical setting. These findings extend prior literature demonstrating that the LCK diet and fat mass reduction are associated with changes in metabolic biomarkers, including fasting insulin and leptin concentration.<sup><xref ref-type="bibr" rid="CIT0003">3</xref>,<xref ref-type="bibr" rid="CIT0009">9</xref>,<xref ref-type="bibr" rid="CIT0010">10</xref>,<xref ref-type="bibr" rid="CIT0012">12</xref>,<xref ref-type="bibr" rid="CIT0016">16</xref></sup> The magnitude of reduction in fasting insulin observed in this series aligns with established mechanisms linking decreased carbohydrate exposure to reduced insulin secretion and improved metabolic flexibility. Insulin resistance is closely associated with excess adiposity, and reductions in circulating insulin are commonly accompanied by decreases in fat mass.<sup><xref ref-type="bibr" rid="CIT0011">11</xref>,<xref ref-type="bibr" rid="CIT0012">12</xref></sup> The 64&#x0025; decline in fasting insulin observed over 12 months was accompanied by favourable changes in metabolic risk markers during the intervention.<sup><xref ref-type="bibr" rid="CIT0007">7</xref>,<xref ref-type="bibr" rid="CIT0009">9</xref>,<xref ref-type="bibr" rid="CIT0012">12</xref>,<xref ref-type="bibr" rid="CIT0016">16</xref></sup> Fasting leptin declined by 80&#x0025; during the intervention, a reduction that exceeded the proportional decrease in total body weight, although leptin decline is expected with adipose tissue reduction.<sup><xref ref-type="bibr" rid="CIT0003">3</xref>,<xref ref-type="bibr" rid="CIT0007">7</xref>,<xref ref-type="bibr" rid="CIT0009">9</xref>,<xref ref-type="bibr" rid="CIT0012">12</xref></sup> The magnitude of this decline relative to weight loss warrants further investigation. Case 1 further illustrates the complexity of this relationship, as substantial weight and leptin reduction occurred despite comparatively little change in fasting insulin. This finding suggests changes in circulating leptin may not parallel changes in fasting insulin. The relative contributions of weight loss, reduced adiposity and the LCK diet to the observed decline in circulating leptin cannot be determined from this case series. Haemoglobin A1c was relatively stable across participants during the 12-month intervention. Although four participants had a history of prediabetes, all six had baseline HbA1c values below 5.9&#x0025;, limiting the opportunity to demonstrate substantial improvement in glycaemic control. Previous studies have reported improvements in glycaemic markers with LCK diet interventions and weight loss.<sup><xref ref-type="bibr" rid="CIT0011">11</xref></sup> In this cohort, however, the modest HbA1c changes are more appropriately interpreted as maintenance of glycaemic stability during substantial weight loss rather than evidence of an LCK diet-specific treatment effect. In a very-low-calorie weight-loss study, a 10-week intervention resulting in approximately 14&#x0025; weight loss was accompanied by substantial reductions in circulating insulin and leptin.<sup><xref ref-type="bibr" rid="CIT0012">12</xref></sup> These findings demonstrate that reductions in insulin and leptin occur with weight loss. Therefore, the extent to which the changes observed in the present case series reflect weight loss, an LCK diet or both cannot be determined.<sup><xref ref-type="bibr" rid="CIT0012">12</xref></sup> While optimal fasting insulin and leptin thresholds remain debated, lower circulating concentrations are generally associated with improved metabolic health and reduced adiposity.<sup><xref ref-type="bibr" rid="CIT0003">3</xref>,<xref ref-type="bibr" rid="CIT0007">7</xref>,<xref ref-type="bibr" rid="CIT0009">9</xref>,<xref ref-type="bibr" rid="CIT0011">11</xref>,<xref ref-type="bibr" rid="CIT0012">12</xref></sup> Following weight loss, mean fasting insulin and leptin concentrations decreased substantially in this cohort. These findings are consistent with an association between LCK diet-supported weight loss and reductions in circulating insulin and leptin; however, these changes cannot be interpreted as direct evidence of improved insulin or leptin sensitivity.</p>
<sec id="s20018">
<title>Strengths and limitations</title>
<p>Strengths of this case series include 12-month follow-up, structured clinical support with repeated behavioural coaching, serial biomarker monitoring and complete follow-up of six participants in a real-world obesity medicine practice. Limitations include the small sample, observational design and absence of a control group, which limit generalisability and preclude causal inference. As a selected, non-random case series, inclusion of participants who completed the 12-month intervention and had baseline and follow-up outcome data available may have introduced selection bias and resulted in a particularly motivated and adherent cohort, further limiting generalisability. The relative contributions of exercise, intermittent fasting, weight loss, behavioural support, reduced adiposity and the LCK diet to the observed outcomes cannot be distinguished. Blood draw timing and pre-draw physical activity were not fully standardised across follow-up measurements, which may have contributed to variability in circulating insulin and leptin concentrations. Intermediate biomarker measurements were not obtained at uniform time points across participants, limiting assessment of the temporal relationship between weight loss and changes in circulating insulin and leptin. Waist circumference and body composition were not systematically assessed, limiting the ability to determine the contribution of fat mass loss to the observed changes in circulating insulin and leptin. Laboratory BHB measurements were not obtained at uniform longitudinal timepoints and therefore could not confirm continuous nutritional ketosis throughout the 12-month intervention.</p>
<p>Real-time laboratory monitoring of fasting BHB for weight loss is highly variable as people transition in and out of nutritional ketosis. Fasting, exercise, ongoing weight loss, and sleep may affect blood BHB levels.<sup><xref ref-type="bibr" rid="CIT0017">17</xref>,<xref ref-type="bibr" rid="CIT0018">18</xref></sup> A limitation of this study is that we relied on self-reported levels of &#x003E; 0.5 mmol/L, and although patients were coached to stay above that level by adjusting their macronutrients to fit the LCK diet throughout the year, laboratory testing intermittently showed they were above the widely accepted BHB threshold of &#x003E; 0.5 mmol/L. Some research shows healthy weight-reduced populations with intermittent BHB levels above 0.1&#x2013;0.3 mmol/L and also that blood BHB levels may fluctuate below 0.5 mmol/L in &#x2018;keto-adapted&#x2019; populations.<sup><xref ref-type="bibr" rid="CIT0017">17</xref>,<xref ref-type="bibr" rid="CIT0018">18</xref>,<xref ref-type="bibr" rid="CIT0019">19</xref></sup></p>
</sec>
<sec id="s20019">
<title>Implications and future directions</title>
<p>The case series suggests that an LCK diet within a structured obesity medicine programme may support clinically meaningful reductions in fasting insulin and leptin. Larger controlled studies are needed to distinguish the relative contributions of an LCK diet, weight loss and behavioural support to these metabolic changes.</p>
</sec>
</sec>
<sec id="s0020">
<title>Conclusion</title>
<p>In this six-patient case series, an LCK diet intervention delivered within a structured obesity medicine programme was associated with clinically meaningful weight loss and reduction in fasting insulin and circulating leptin, with HbA1c remaining relatively stable over 12 months. Because of the observational design, small sample size and lack of a control group, these findings should be interpreted cautiously. Larger controlled studies are still needed to clarify the relative contributions of weight loss, an LCK diet and behavioural support to the observed metabolic changes.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<sec id="s20021" sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.</p>
</sec>
<sec id="s20022">
<title>CRediT authorship contribution</title>
<p>Jeffrey R. Pua: Conceptualisation, Data curation, Formal analysis, Investigation, Methodology, Resources, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. Melanie M. Tidman: Conceptualisation, Formal analysis, Investigation, Project administration, Resources, Software, Supervision, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. Dawn R. White: Methodology, Software, Supervision, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. Tim A. White: Software, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. All authors reviewed the article, contributed to the discussion of results, approved the final version for submission and publication, and take responsibility for the integrity of its findings.</p>
</sec>
<sec id="s20023" sec-type="data-availability">
<title>Data availability</title>
<p>The data that support the findings of this study are available on request from the corresponding author, Melanie M. Tidman.</p>
</sec>
<sec id="s20024">
<title>Disclaimer</title>
<p>The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any affiliated agency of the authors, or that of the publisher. The authors are responsible for this article&#x2019;s results, findings, and content.</p>
</sec>
</ack>
<ref-list id="references">
<title>References</title>
<ref id="CIT0001"><label>1</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>American Board of Obesity Medicine</collab></person-group>. <source>Certifying physicians in the treatment of obesity</source>. <publisher-loc>Denver (CO)</publisher-loc>: <publisher-name>American Board of Obesity Medicine</publisher-name>; <year>2023</year> <comment>[cited n.d.]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.abom.org/">https://www.abom.org/</ext-link></comment></mixed-citation></ref>
<ref id="CIT0002"><label>2</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Obesity Medicine Association</collab></person-group>. <source>Obesity medicine association: Membership, education, and resources [homepage on the Internet]</source>. <publisher-name>Obesity Medicine Association</publisher-name>; <year>2026</year> <comment>[cited 2026 Jan 25]. Available from: <ext-link ext-link-type="uri" xlink:href="https://obesitymedicine.org">https://obesitymedicine.org</ext-link></comment></mixed-citation></ref>
<ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname> <given-names>S</given-names></string-name>, <string-name><surname>Li</surname> <given-names>N</given-names></string-name>, <string-name><surname>Xiong</surname> <given-names>W</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Leptin reduction as a required component for weight loss</article-title>. <source>Diabetes</source>. <year>2024</year>;<volume>73</volume>(<issue>2</issue>):<fpage>197</fpage>&#x2013;<lpage>210</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2337/db23-0571">https://doi.org/10.2337/db23-0571</ext-link></comment></mixed-citation></ref>
<ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reaven</surname> <given-names>GM</given-names></string-name></person-group>. <article-title>Role of insulin resistance in human disease</article-title>. <source>Diabetes</source>. <year>1988</year>;<volume>37</volume>(<issue>12</issue>):<fpage>1595</fpage>&#x2013;<lpage>1607</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2337/diab.37.12.1595">https://doi.org/10.2337/diab.37.12.1595</ext-link></comment></mixed-citation></ref>
<ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ludwig</surname> <given-names>DS</given-names></string-name>, <string-name><surname>Aronne</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Astrup</surname> <given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The carbohydrate-insulin model: A physiological perspective on the obesity pandemic</article-title>. <source>Am J Clin Nutr</source>. <year>2021</year>;<volume>114</volume>(<issue>6</issue>):<fpage>1873</fpage>&#x2013;<lpage>1885</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/ajcn/nqab270">https://doi.org/10.1093/ajcn/nqab270</ext-link></comment></mixed-citation></ref>
<ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Obradovic</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sudar-Milovanovic</surname> <given-names>E</given-names></string-name>, <string-name><surname>Soskic</surname> <given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Leptin and obesity: Role and clinical implication</article-title>. <source>Front Endocrinol</source>. <year>2021</year>;<volume>12</volume>:<fpage>585887</fpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2021.585887">https://doi.org/10.3389/fendo.2021.585887</ext-link></comment></mixed-citation></ref>
<ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Izquierdo</surname> <given-names>AG</given-names></string-name>, <string-name><surname>Crujeiras</surname> <given-names>AB</given-names></string-name>, <string-name><surname>Casanueva</surname> <given-names>FF</given-names></string-name>, <string-name><surname>Carreira</surname> <given-names>MC</given-names></string-name></person-group>. <article-title>Leptin, obesity, and leptin resistance: Where are we 25 years later?</article-title> <source>Nutrients</source>. <year>2019</year>;<volume>11</volume>(<issue>11</issue>):<fpage>2704</fpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/nu11112704">https://doi.org/10.3390/nu11112704</ext-link></comment></mixed-citation></ref>
<ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Relationship between body composition, insulin resistance, and hormonal profiles in women with polycystic ovary syndrome</article-title>. <source>Front Endocrinol</source>. <year>2023</year>;<volume>13</volume>:<fpage>1085656</fpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2022.1085656">https://doi.org/10.3389/fendo.2022.1085656</ext-link></comment></mixed-citation></ref>
<ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Paoli</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bianco</surname> <given-names>A</given-names></string-name>, <string-name><surname>Moro</surname> <given-names>T</given-names></string-name>, <string-name><surname>Mota</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Coelho-Ravagnani</surname> <given-names>CF</given-names></string-name></person-group>. <article-title>The effects of ketogenic diet on insulin sensitivity and weight loss, which came first: The chicken or the egg?</article-title> <source>Nutrients</source>. <year>2023</year>;<volume>15</volume>(<issue>14</issue>):<fpage>3120</fpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/nu15143120">https://doi.org/10.3390/nu15143120</ext-link></comment></mixed-citation></ref>
<ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mashayekhi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Nian</surname> <given-names>H</given-names></string-name>, <string-name><surname>Mayfield</surname> <given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Weight loss-independent effect of Liraglutide on insulin sensitivity in individuals with obesity and prediabetes</article-title>. <source>Diabetes</source>. <year>2024</year>;<volume>73</volume>(<issue>1</issue>):<fpage>38</fpage>&#x2013;<lpage>50</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2337/db23-0356">https://doi.org/10.2337/db23-0356</ext-link></comment></mixed-citation></ref>
<ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shai</surname> <given-names>J</given-names></string-name>, <string-name><surname>Schwarzfuchs</surname> <given-names>D</given-names></string-name>, <string-name><surname>Henkin</surname> <given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>359</volume>:<fpage>229</fpage>&#x2013;<lpage>241</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa0708681">https://doi.org/10.1056/NEJMoa0708681</ext-link></comment></mixed-citation></ref>
<ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sumithran</surname> <given-names>P</given-names></string-name>, <string-name><surname>Prendergast</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Delbridge</surname> <given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Long-term persistence of hormonal adaptations to weight loss</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>:<fpage>1597</fpage>&#x2013;<lpage>1604</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1105816">https://doi.org/10.1056/NEJMoa1105816</ext-link></comment></mixed-citation></ref>
<ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Guan</surname> <given-names>B</given-names></string-name></person-group>. <article-title>Change in adipokines and gastrointestinal hormones after bariatric surgery: A meta-analysis</article-title>. <source>Obes Surg</source>. <year>2023</year>;<volume>33</volume>(<issue>3</issue>):<fpage>789</fpage>&#x2013;<lpage>806</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11695-022-06444-8">https://doi.org/10.1007/s11695-022-06444-8</ext-link></comment></mixed-citation></ref>
<ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rice</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Reynolds</surname> <given-names>DB</given-names></string-name></person-group>. <article-title>Practical guidelines for addressing common questions and misconceptions about the ketogenic diet</article-title>. <source>J Metab Health</source>. <year>2024</year>;<volume>8</volume>(<issue>1</issue>):<fpage>a113</fpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4102/jmh.v8i1.113">https://doi.org/10.4102/jmh.v8i1.113</ext-link></comment></mixed-citation></ref>
<ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Prochaska</surname> <given-names>JO</given-names></string-name>, <string-name><surname>DiClemente</surname> <given-names>CC</given-names></string-name></person-group>. <article-title>Stages and processes of self-change of smoking: Toward an integrative model of change</article-title>. <source>J Consult Clin Psychol</source>. <year>1983</year>;<volume>51</volume>(<issue>3</issue>):<fpage>390</fpage>&#x2013;<lpage>395</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1037/0022-006X.51.3.390">https://doi.org/10.1037/0022-006X.51.3.390</ext-link></comment></mixed-citation></ref>
<ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Silva</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Do Carmo</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Li</surname> <given-names>X</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Mouton</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Hall</surname> <given-names>JE</given-names></string-name></person-group>. <article-title>Role of hyperinsulinemia and insulin resistance in hypertension: Metabolic syndrome revisited</article-title>. <source>Can J Cardiol</source>. <year>2020</year>;<volume>36</volume>(<issue>5</issue>):<fpage>671</fpage>&#x2013;<lpage>682</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cjca.2020.02.066">https://doi.org/10.1016/j.cjca.2020.02.066</ext-link></comment></mixed-citation></ref>
<ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>SR</given-names></string-name>, <string-name><surname>Cho</surname> <given-names>W</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Short-term isocaloric ketogenic diet modulates NLRP3 inflammasome via B-hydroxybutyrate and fibroblast growth factor 21</article-title>. <source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<fpage>843520</fpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2022.843520">https://doi.org/10.3389/fimmu.2022.843520</ext-link></comment></mixed-citation></ref>
<ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anderson</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mattar</surname> <given-names>SG</given-names></string-name>, <string-name><surname>Greenway</surname> <given-names>FL</given-names></string-name>, <string-name><surname>Lindquist</surname> <given-names>RJ</given-names></string-name></person-group>. <article-title>Measuring ketone bodies for the monitoring of pathologic and therapeutic ketosis</article-title>. <source>Obes Sci Pract</source>. <year>2021</year>;<volume>7</volume>(<issue>5</issue>):<fpage>646</fpage>&#x2013;<lpage>656</lpage>. <comment><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/osp4.516">https://doi.org/10.1002/osp4.516</ext-link></comment></mixed-citation></ref>
<ref id="CIT0019"><label>19</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Volek</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Phinney</surname> <given-names>SD</given-names></string-name></person-group>. <source>The art and science of low carbohydrate living: An expert guide to making the life-saving benefits of carbohydrate restriction sustainable and enjoyable</source>. <publisher-loc>Lexington (KY)</publisher-loc>: <publisher-name>Beyond Obesity LLC.</publisher-name>, <year>2011</year>; <fpage>316</fpage> p.</mixed-citation></ref>
</ref-list>
<fn-group>
<fn><p><bold>How to cite this article:</bold> Pua JR, Tidman MM, White DR, White TA. Targeting insulin and leptin in obesity management: A case series in metabolic health practice. J. metab. health. 2026;9(1), a148. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4102/jmh.v9i1.148">https://doi.org/10.4102/jmh.v9i1.148</ext-link></p></fn>
</fn-group>
</back>
</article>